Company Performance - Enanta Pharmaceuticals reported a quarterly loss of $1.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.16, and compared to a loss of $1.33 per share a year ago, indicating a surprise of -17.24% [1] - The company posted revenues of $14.61 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 20.68%, and down from $18.93 million in the same quarter last year [2] - Over the last four quarters, Enanta Pharmaceuticals has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Future Outlook - The current consensus EPS estimate for the coming quarter is -$1.24 on revenues of $17.19 million, and for the current fiscal year, it is -$5.02 on revenues of $80.53 million [7] - The estimate revisions trend for Enanta Pharmaceuticals is mixed, leading to a Zacks Rank 3 (Hold), suggesting the shares are expected to perform in line with the market in the near future [6] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] Industry Context - The Medical - Drugs industry, to which Enanta Pharmaceuticals belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the performance of stocks within the industry [5]

Financial Performance - Total revenue for Q4 2024 was $14.6 million, down from $18.9 million in Q4 2023, and total revenue for the fiscal year was $67.6 million compared to $79.2 million in 2023, reflecting a decline due to decreased sales of AbbVie's MAVYRET®/MAVIRET®[4] - Net loss for Q4 2024 was $28.8 million, or a loss of $1.36 per diluted share, compared to a net loss of $28.1 million, or a loss of $1.33 per diluted share in Q4 2023; for the fiscal year, net loss was $116.0 million, or a loss of $5.48 per diluted share, compared to a net loss of $133.8 million, or a loss of $6.38 per diluted share in 2023[10] - Revenue for September 2024 was $14,607 million, a decrease of 30% from $18,932 million in September 2023[21] - Net loss for September 2024 was $28,823 million, compared to a net loss of $28,107 million in September 2023, indicating a slight increase in losses[21] - Net loss per share (basic and diluted) for September 2024 was $(1.36), compared to $(1.33) in September 2023[21] Research and Development - Research and development expenses decreased to $30.8 million in Q4 2024 from $36.2 million in Q4 2023, and for the fiscal year, expenses were $131.5 million compared to $163.5 million in 2023, primarily due to reduced costs associated with the COVID-19 program[6] - Positive topline results for EDP-323 in a Phase 2a study showed statistically significant reductions in viral load and clinical symptoms compared to placebo, indicating a strong potential for RSV treatment[13] - Enanta is on track to report topline results for the RSVPEDs study of zelicapavir in December 2024, which could position the company with two leading clinical candidates for RSV treatment[3] - The company has nominated EPS-1421 as its lead development candidate for its KIT inhibition program, targeting chronic spontaneous urticaria and other mast cell-driven diseases[14] - Enanta's second discovery program focuses on developing oral STAT6 inhibitors for type 2 immune-driven diseases, with initial efforts aimed at atopic dermatitis[14] Expenses and Liabilities - Interest expense for Q4 2024 was $2.6 million, compared to $3.2 million in Q4 2023, while total interest expense for the fiscal year was $10.9 million, up from $5.1 million in 2023[5] - Total operating expenses decreased to $44,461 million in September 2024 from $49,962 million in September 2023, representing a reduction of approximately 10%[21] - Research and development expenses were $30,778 million in September 2024, down from $36,167 million in September 2023, a decrease of about 15%[21] - Interest expense decreased to $2,581 million in September 2024 from $3,151 million in September 2023, a reduction of about 18%[21] - A portion of ongoing royalty revenue (54.5%) from AbbVie's sales is paid to OMERS, with the upfront purchase payment of $200.0 million recorded as a liability[5] Cash and Assets - Enanta has $248.2 million in cash and marketable securities as of September 30, 2024, which is expected to be sufficient to meet anticipated cash requirements into fiscal 2027[11] - Cash and cash equivalents decreased to $37,233 million as of September 30, 2024, from $85,388 million as of September 30, 2023, a decline of approximately 56%[24] - Total assets decreased to $376,652 million in September 2024 from $462,275 million in September 2023, a reduction of about 19%[24] - Total stockholders' equity fell to $128,814 million in September 2024, down from $216,735 million in September 2023, a decrease of approximately 41%[24] - Current liabilities decreased slightly to $57,535 million in September 2024 from $62,787 million in September 2023[24]

Company Overview - Enanta Pharmaceuticals (ENTA) shares increased by 5.6% to close at $10.94, following a period of 19.6% loss over the past four weeks, indicating a significant recovery in trading volume [1] - The company is a member of the Zacks Medical - Drugs industry, which includes other companies like BioCryst Pharmaceuticals (BCRX) [4] Recent Developments - Enanta Pharmaceuticals announced positive top-line data from a phase IIa human challenge study for its candidate EDP-323, showing significant reductions in viral load and clinical symptoms in healthy adults infected with respiratory syncytial virus [2] - The consensus EPS estimate for Enanta's upcoming quarterly report has been revised 5.3% higher over the last 30 days, suggesting a positive trend that may lead to further price appreciation [4] Financial Expectations - The company is expected to report a quarterly loss of $1.16 per share, reflecting a year-over-year change of +12.8%, with revenues projected at $18.73 million, down 1.1% from the previous year [3] - BioCryst Pharmaceuticals, a peer in the industry, has an unchanged EPS estimate of -$0.07, which represents a 63.2% improvement from the prior year [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ENTA NASDAQ Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissio ...

Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 • Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 • Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retai ...

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Enanta Pharmaceuticals (ENTA) shares rallied 6.7% in the last trading session to close at $16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.6% gain over the past four weeks. Enanta Pharmaceuticals is a member of the Zacks Medical - Drugs industry. One other stock in th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, par value $0.0 ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus - Chief Medical Officer Tara Kieffer - Chief Product Strategy Officer Conference Call Participants Eric Joseph - JPMorgan Roy Buchanan - Citizens JMP Nik Gasic - Leerink Partners Jay Olson - Oppenheimer Operator Good afternoon and welcome to Enanta ...

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.18 per share when it actually produced a loss of $1.58, delivering a surprise of -33.90%.Over the last four quarters, t ...

Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET WATERTOWN, Mass., May 6, 2024 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. "At Enanta, we are committed to advancing the first antiviral treatment for RSV, ...